Medical device delivery system with alignment feature

Information

  • Patent Grant
  • 11147668
  • Patent Number
    11,147,668
  • Date Filed
    Thursday, February 7, 2019
    5 years ago
  • Date Issued
    Tuesday, October 19, 2021
    2 years ago
Abstract
A delivery system for delivering an implantable heart valve includes an outer shaft and an inner shaft that is slidingly disposable within an outer shaft lumen, the inner shaft including a distal end region. A plurality of fingers extend distally relative to the distal end region of the inner shaft and are adapted to releasably engage an implantable heart valve. A plurality of looped sheathing aids extend distally from the distal region of an inner shaft lumen and are adapted to guide the implantable heart valve back into the outer shaft lumen when the implantable heart valve is pulled back into the outer shaft lumen. Each of the plurality of looped sheathing aids include a distal petal adapted to engage tissue adjacent a native valve annulus in order to limit distal advancement of the implantable heart valve during deployment of the implantable heart valve.
Description
TECHNICAL FIELD

The present disclosure pertains generally to valve delivery devices and more particularly to valve delivery devices that facilitate alignment of the valve to the native annulus.


BACKGROUND

Medical devices typically used for cardiovascular system treatments may involve complex and invasive therapies resulting in significant discomfort, pain, and long recovery times for patients. Recently, less invasive, percutaneous treatments have been developed. There is an ongoing need for improved, less invasive cardiovascular treatments.


SUMMARY

The disclosure provides design, material, and manufacturing method alternatives for valve delivery devices, particularly valve delivery devices that facilitate coaxial alignment of the valve with the native annulus. An example of the disclosure is a delivery system for delivering an implantable heart valve. The delivery system includes an outer shaft having an outer shaft lumen extending therethrough and an inner shaft that is slidingly disposable within the outer shaft lumen and includes a distal end region, the inner shaft defining an inner shaft lumen therethrough. A plurality of fingers extend distally relative to the distal end region of the inner shaft and are adapted to releasably engage an implantable heart valve. A plurality of looped sheathing aids extend distally from the distal region of the inner shaft lumen and are adapted to guide the implantable heart valve back into the outer shaft lumen when the implantable heart valve is pulled back into the outer shaft lumen. Each of the plurality of looped sheathing aids include a distal petal adapted to engage tissue adjacent a native valve annulus in order to limit distal advancement of the implantable heart valve during deployment of the implantable heart valve.


Alternatively or additionally to any embodiment above, each of the plurality of looped sheathing aids may include a length of wire shaped into a first leg and a second leg, with the distal petal therebetween.


Alternatively or additionally to any embodiment above, each of the plurality of looped sheathing aids may be laser cut from a piece of metal to include a first leg, a second leg, with the distal petal therebetween.


Alternatively or additionally to any embodiment above, each of the plurality of looped sheathing aids may be adapted to be manually adjusted in shape prior to use.


Alternatively or additionally to any embodiment above, each of the plurality of looped sheathing aids may include stainless steel.


Alternatively or additionally to any embodiment above, each of the plurality of looped sheathing aids may be biased into a configuration in which each distal petal is positioned to engage the tissue adjacent a native valve annulus and may be further adapted to deflect away from the biased shape for advancing the delivery system into a position in which the implantable heart valve is positioned proximate the native valve annulus.


Alternatively or additionally to any embodiment above, each of the plurality of looped sheathing aids may include a shape memory material.


Alternatively or additionally to any embodiment above, each of the plurality of looped sheathing aids may include a nickel titanium alloy.


Alternatively or additionally to any embodiment above, the implantable heart valve may include an implantable aortic valve, and each of the plurality of looped sheathing aids may include a distal petal adapted to engage a sinus of Valsalva adjacent a native aortic annulus.


Alternatively or additionally to any embodiment above, the delivery device may further include a coupler that is secured to the distal end region and defines a coupler lumen extending therethrough in coaxial alignment with the inner shaft lumen. The plurality of fingers extend distally from the coupler and the plurality of looped sheathing aids extend distally from within the coupler lumen.


Alternatively or additionally to any embodiment above, the plurality of fingers may be part of a tubular member forming the coupler.


Another example of the disclosure is a delivery system for delivering an implantable heart valve. The delivery system includes an outer sheath that is adapted to reversibly house the implantable heart valve therein. An inner member is slidingly disposed within the outer sheath and defines an inner member lumen. The inner member is adapted to releasably secure the implantable heart valve and to advance the implantable heart valve from a position within the outer sheath to a position distal of the outer sheath. Three looped sheathing aids extend distally through the inner member lumen, each of the three looped sheathing aids including a distal petal that is adapted to engage tissue proximate a native valve annulus in order to limit distal travel of the delivery system. The three looped sheathing aids are adapted to guide the implantable heart valve back into the sheath when the implantable heart valve is pulled back into the sheath.


Alternatively or additionally to any embodiment above, the inner member may include three fingers that extend distally from the inner member and that may be adapted to releasably engage the implantable heart valve.


Alternatively or additionally to any embodiment above, each of the three looped sheathing aids may be biased into a configuration in which each distal petal is positioned to engage the tissue adjacent a native valve annulus and may be further adapted to deflect away from the biased shape for advancing the delivery system into a position in which the implantable heart valve is positioned proximate the native valve annulus.


Alternatively or additionally to any embodiment above, each of the three looped sheathing aids may include a shape memory material.


Alternatively or additionally to any embodiment above, each of the three looped sheathing aids may include a nickel titanium alloy.


Alternatively or additionally to any embodiment above, the implantable heart valve may include an implantable aortic valve, and each of the three looped sheathing aids may include a distal petal adapted to engage a sinus of Valsalva adjacent a native aortic annulus.


Another example of the disclosure is a delivery system for delivering an implantable aortic valve. The delivery system includes an outer sheath that is adapted to reversibly house the implantable aortic valve therein and an inner member that is slidingly disposed within the outer sheath. The inner member defines an inner member lumen and is adapted to releasably secure the implantable aortic valve and to advance the implantable aortic valve from a position within the outer sheath to a position distal of the outer sheath. Three looped sheathing aids extend distally through the inner member lumen, each of the three looped sheathing aids including a distal petal that is adapted to engage a sinus of Valsalva adjacent a native aortic annulus in order to limit distal travel of the delivery system.


Alternatively or additionally to any embodiment above, the three looped sheathing aids may be further adapted to guide the implantable heart valve back into the sheath when the implantable aortic valve is pulled back into the sheath.


Alternatively or additionally to any embodiment above, each of the three looped sheathing aids may be formed to include a first leg and a second leg with the distal petal disposed therebetween.


The above summary of some embodiments is not intended to describe each disclosed embodiment or every implementation of the present invention. The Figures, and Detailed Description, which follow, more particularly exemplify these embodiments.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which:



FIG. 1 is side view of an example medical device system;



FIG. 2 is a cross-sectional side view of an example outer sheath;



FIG. 3 is a transverse cross-sectional view taken through line 3-3 in FIG. 2;



FIG. 4 is a perspective view of an example inner catheter;



FIG. 5 is a cross-sectional view taken through line 5-5 in FIG. 4;



FIG. 6 is a cross-sectional view taken through line 6-6 in FIG. 4;



FIG. 7 is a perspective view of a portion of an example implant associated with the example medical device system;



FIG. 8 through FIG. 11 are perspective views that illustrate an example mechanism for locking an implant;



FIG. 12 is a side view of a delivery system including a plurality of looped sheathing aids;



FIG. 13 is a side view of the delivery system of FIG. 12, shown with a sheath partially advanced over the plurality of looped sheathing aids;



FIG. 14 is a side view of the delivery system of FIG. 12, shown with the sheath more fully advanced over the plurality of looped sheathing aids;



FIG. 15 is a schematic top view of a native aortic valve annulus;



FIG. 16 is a perspective view of an example inner catheter; and



FIG. 17 is a perspective view of a portion of an example implant associated with the example medical device system.





While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the disclosure to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.


DETAILED DESCRIPTION

For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.


All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the term “about” may include numbers that are rounded to the nearest significant figure.


The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).


As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.


The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.


Diseases and/or medical conditions that impact the cardiovascular system are prevalent in the United States and throughout the world. Traditionally, treatment of the cardiovascular system was often conducted by directly accessing the impacted part of the system. For example, treatment of a blockage in one or more of the coronary arteries was traditionally treated using coronary artery bypass surgery. As can be readily appreciated, such therapies are rather invasive to the patient and require significant recovery times and/or treatments. More recently, less invasive therapies have been developed, for example, where a blocked coronary artery could be accessed and treated via a percutaneous catheter (e.g., angioplasty). Such therapies have gained wide acceptance among patients and clinicians.


Some relatively common medical conditions may include or be the result of inefficiency, ineffectiveness, or complete failure of one or more of the valves within the heart. For example, failure of the aortic valve can have a serious effect on a human and could lead to serious health condition and/or death if not dealt with. Treatment of defective heart valves poses other challenges in that the treatment often requires the repair or outright replacement of the defective valve. Such therapies may be highly invasive to the patient. Disclosed herein are medical devices that may be used for delivering a medical device to a portion of the cardiovascular system in order to diagnose, treat, and/or repair the system. At least some of the medical devices disclosed herein may be used to deliver and implant a replacement heart valve (e.g., a replacement aortic valve). In addition, the devices disclosed herein may deliver the replacement heart valve percutaneously and, thus, may be much less invasive to the patient. The devices disclosed herein may also provide a number of additional desirable features and benefits as described in more detail below.



FIG. 1 is a side view of an example medical device system 10. It should be noted that some features of the system 10 are either not shown, or are shown schematically, in FIG. 1 for simplicity. Additional details regarding some of the components of the system 10 are provided in other figures in greater detail. The system 10 may be used to deliver and/or deploy a variety of medical devices to a number of locations within the anatomy. In at least some cases, the system 10 is a replacement heart valve delivery system (e.g., a replacement aortic valve delivery system) that can be used for percutaneous delivery of a replacement heart valve. This, however, is not intended to be limiting as the system 10 may also be used for other interventions including mitral valve replacement, valve repair, valvuloplasty, and the like, or other similar interventions.


The system 10 may generally be described as a catheter system that includes an outer sheath or catheter 12 and an inner catheter or tube 14 (a portion of which is shown in FIG. 1 in phantom line) extending at least partially through the outer sheath 12. A medical device implant 16 may be coupled to the inner catheter 14 and disposed within the outer sheath 12 during delivery of the implant 16. A handle 18 may be disposed at the proximal end of the outer sheath 12 and the inner catheter 14. In general, the handle 18 may be configured to manipulate the position of the outer sheath 12 relative to the inner catheter 14 as well as aid in the deployment of the implant 16.


In use, the system 10 may be advanced percutaneously through the vasculature to a position adjacent to an area of interest. For example, the system 10 may be advanced through the vasculature to a position adjacent to a defective aortic valve. During delivery, the implant 16 may be generally disposed in an elongated and low profile “delivery” configuration within the outer sheath 12. Once positioned, the outer sheath 12 may be retracted to expose the implant 16. The implant 16 may be actuated in order to expand implant into a generally shortened and larger profile “deployed” configuration suitable for implantation within the anatomy. When the implant 16 is suitably deployed within the anatomy, the system 10 can be removed from the vasculature, leaving the implant 16 in place to function as, for example, a suitable replacement for the native aortic valve. In at least some interventions, the implant 16 may be deployed within the native valve (e.g., the native valve is left in place and not excised). Alternatively, the native valve may be removed and implant 16 may be deployed in its place as a replacement.



FIG. 2 through FIG. 11 illustrate some of the components of the system 10. For example, FIG. 2 is a cross-sectional side view of the outer sheath 12. Here it can be seen that the outer sheath 12 has a proximal portion 20 and a distal portion 22. The distal portion 22 may have a slightly enlarged or flared inner diameter, which may provide additional space for holding the implant 16 therein. For example, the inner diameter of the outer sheath 12 along the proximal portion 20 may be in the range of about 0.254 to 1.27 cm (0.10 to 0.50 inches), or about 0.508 to 1.016 cm (0.20 to 0.40 inches), or about 0.508 to 0.762 cm (0.20 to 0.30 inches), or about 0.56388±0.0508 cm (0.222±0.002 inches). The inner diameter of the outer sheath 12 along the distal portion 22 may be in the range of about 0.254 to 1.27 cm (0.10 to 0.50 inches), or about 0.508 to 1.016 cm (0.20 to 0.40 inches), or about 0.508 to 0.762 cm (0.20 to 0.30 inches), or about 0.579 to 0.5842 cm (0.228 to 0.230 inches). At the distal end of the distal portion 22 may be a distal tip 24, which may be flared or otherwise have a funnel-like shape. The funnel-like shape increases the outer diameter (and inner diameter) of the outer sheath 12 at the distal tip 24 and may aid in the sheathing and/or re-sheathing of the implant 16 into the outer sheath 12. Other than at the distal tip 24, the outer sheath 12 may have a generally constant outer diameter. For example, the outer sheath 12 may have an outer diameter in the range of about 0.254 to 1.27 cm (0.10 to 0.50 inches), or about 0.508 to 1.016 cm (0.20 to 0.40 inches), or about 0.508 to 0.762 cm (0.20 to 0.30 inches), or about 0.6858 cm (0.270 inches). These are just examples. Other embodiments are contemplated that have differing dimensions (including those appropriate for differently sized patients including children) and/or arrangements for the outer diameter and/or inner diameter of the outer sheath 12. These contemplated embodiments include outer sheaths with flared or otherwise variable outer diameters, embodiments with constant inner diameters, combinations thereof, and the like. The outer sheath 12 may also have a length that is appropriate for reaching the intended area of interest within the anatomy. For example, the outer sheath 12 may have a length in the range of about 30 to 200 cm, or about 60 to 150 cm, or about 100 to 120 cm, or about 108±0.20 cm. The outer sheath 12 may also be curved. For example, a distal section of the outer sheath 12 may be curved. In one example, the radius of the curve (measured from the center of the outer sheath 12) may be in the range of about 2 to 6 cm (20 to 60 mm), or about 3 to 4 cm (30 to 40 mm), or about 3.675 cm (36.75 mm). Again, these dimensions are examples and are not intended to be limiting.


The outer sheath 12 may be formed from a singular monolithic tube or unitary member. Alternatively, the outer sheath 12 may include a plurality of layers or portions. One or more of these layers may include a reinforcing structure such as a braid, coil, mesh, combinations thereof, or the like. FIG. 3 is a cross-section taken along line 3-3 of FIG. 2 illustrating one example of a multilayer structure for the outer sheath 12. For example, the outer sheath 12 may include an inner liner or layer 26. An intermediate or tier layer 28 may be disposed on the inner liner 26. A reinforcement 30 may be disposed on the intermediate layer 28. A topcoat or outer layer 32 may be disposed on the reinforcement 30. Finally, an outer coating 34 (e.g., a lubricious coating, a hydrophilic coating, a hydrophobic coating, etc.) may be disposed along portions or all of the topcoat 32. These are just examples. Several alternative structural configurations are contemplated for the outer sheath 12 including embodiments including two or more layers that may be different from those shown in FIG. 3, embodiments without a reinforcement, and the like, or other suitable configurations.


The dimensions and materials utilized for the various layers of the outer sheath 12 may also vary. For example, the inner liner 26 may include a polymeric material such as fluorinated ethylene propylene (FEP) and may have a thickness in the range of about 0.00254 to 0.0127 cm (0.001 to 0.005 inches) or about 0.00762±0.00254 (0.003±0.001 inches), the intermediate layer 28 may include a polymer material such as polyether block amide (e.g., PEBAX 6333) and may have a thickness in the range of about 0.00254 to 0.0127 cm (0.001 to 0.005 inches) or about 0.00508±0.00254 (0.002±0.001 inches), the outer coating 34 may include a polymer material such as polyether block amide (e.g., PEBAX 7233) and may have a thickness in the range of about 0.00254 to 0.0254 cm (0.001 to 0.01 inches). In some embodiments, the outer coating 34 may vary in thickness. For example, along the proximal portion 20 the outer coating 34 may have greater thickness, such as about 0.0127 to about 0.0508 cm or about 0.02159 cm (0.005 to 0.02 inches or about 0.0085 inches), than along the distal portion 22 and/or the distal tip 24, which may be about 0.0127 to about 0.0508 cm or about 0.01651 cm (e.g., about 0.005 to 0.02 inches or about 0.0065 inches). These are just examples as other suitable materials may be used.


The form of the distal tip 24 may also vary. For example, in at least some embodiments, the inner liner 26 (i.e., a 2.5 mm section thereof) may be extended up and around the distal end of the outer sheath 12 (e.g., around the reinforcement 30 and the topcoat 32). A ring member (not shown) made from a suitable material such as a 55D polyether block amide (e.g., 55D PEBAX) may be disposed over the inner liner 26 and heat bonded to form the distal tip 24. This may form the funnel-like shape of the distal tip 24.


The reinforcement 30 may also vary in form. In at least some embodiments, the reinforcement 30 may take the form of a braid, coil, mesh, or the like. For example, in some embodiments, the reinforcement 30 may include a metallic braid (e.g., stainless steel). In some of these embodiments, the reinforcement 30 may also include additional structures such as one or more longitudinally-extending strands. For example, the reinforcement 30 may include a pair of longitudinally-extending aramid and/or para aramid strands (for example, KEVLAR®) disposed on opposite sides of the braid. These strands may or may not be woven into portions or all of the braid.



FIG. 4 is a perspective view of the inner catheter 14. A distal end region of the inner catheter 14 may include a step 40 in outer diameter that defines a decreased outer diameter section 42. For example, the decreased outer diameter section 42 may have an outer diameter in the range of about 0.127 to 0.635 cm (0.05 to 0.25 inches), or about 0.254 to 0.508 cm (0.10 to 0.20 inches), or about 0.38608±0.00762 (0.152±0.003 inches) as opposed to the remainder of the inner catheter 14 where the outer diameter may be in the range of about 0.127 to 0.762 cm (0.05 to 0.30 inches), or about 0.254 to 0.635 cm (0.10 to 0.25 inches), or about 0.508±0.0254 cm (0.20±0.01 inches). The decreased outer diameter section 42 may define a region where other components of the system 10 may be attached. Some additional details regarding these components can be found herein.


In general, the inner catheter 14 may take the form of an extruded polymer tube. Other forms are also contemplated including other polymer tubes, metallic tubes, reinforced tubes, or the like including other suitable materials such as those disclosed herein. In some embodiments, the inner catheter 14 is a singular monolithic or unitary member. In other embodiments, the inner catheter 14 may include a plurality of portions or segments that are coupled together. The total length of the inner catheter may be in the range of about 60 to 150 cm, or about 80 to 120 cm, or about 100 to 115 cm, or about 112±0.02 cm. Just like the outer sheath 12, the inner catheter 14 may also be curved, for example adjacent to the distal end thereof. In some embodiments, the inner catheter 14 may have one or more sections with a differing hardness/stiffness (e.g., differing shore durometer). For example, the inner catheter may have a proximal region 44a and an intermediate region 44b. The proximal region 44a may include a generally stiff polymeric material such as a 72D polyether block amide (e.g., 72D PEBAX) and may have a length in the range of about 60 to 150 cm, or about 80 to 120 cm, or about 100 to 115 cm, or about 109.5±0.02 cm. The intermediate region 44b may include a 40D polyether block amide (e.g., 40D PEBAX) and may have a length in the range of about 5 to 25 mm, or about 10 to 20 mm, or about 15±0.01 mm. The decreased outer diameter section 42 may also differ from regions 44a/44b and, in some embodiments, may include a 72D polyether block amide (e.g., 72D PEBAX) and may have a length in the range of about 0.5 to 2 cm (5 to 20 mm), or about 0.8 to 1.5 cm (8 to 15 mm), or about 1±0.001 cm (10±0.01 mm). These are just examples.


The inner catheter 14 may include one or more lumens. For example, FIG. 5, a cross-sectional view of the inner catheter 14 adjacent to a proximal end portion 36 taken at line 5-5 in FIG. 4, illustrates that the inner catheter 14 may include a first lumen 46, a second lumen 48, a third lumen 50, and a fourth lumen 52. In general, the lumens 46/48/50/52 extend along the entire length of the inner catheter 14. Other embodiments are contemplated, however, where one or more of the lumens 46/48/50/52 extend along only a portion of the length of the inner catheter 14. For example, the fourth lumen 52 may stop just short of the distal end of the inner catheter 14 and/or be filled in at its distal end to effectively end the fourth lumen 52 proximal of the distal end of the inner catheter 14. For example, as illustrated in FIG. 6, which is a cross-sectional view of the inner catheter 14 taken at line 6-6 in FIG. 4, the fourth lumen 52 is absent.


Disposed within the first lumen 46 may be push-pull rods 84 (not shown in FIG. 5, seen in other figures including FIG. 7), which are used to expand and/or elongate the implant 16 as explained in more detail herein. In at least some embodiments, the first lumen 46 may be lined with a low friction liner 54 (e.g., a FEP liner). Disposed within the second lumen 48 may be a pin release mandrel 92 (not shown in FIG. 5, seen in other figures including FIG. 7), which is explained in more detail herein. In at least some embodiments, the second lumen 48 may be lined with a hypotube liner 56. The third lumen 50 may be a guidewire lumen and this lumen may also be lined with a hypotube liner 58.


The fourth lumen 52 may be used to house a non-stretch wire 60. The form of the non-stretch wire 60 may vary. In some embodiments, the non-stretch wire 60 may take the form of a stainless steel braid. The non-stretch wire 60 may optionally include a pair of longitudinally-extending aramid and/or para aramid strands (for example, KEVLAR®) disposed on opposite sides of the braid. In general, rather than being “disposed within” the fourth lumen 52, the non-stretch wire 60 may be embedded within the fourth lumen 52. In addition, the non-stretch wire 60 may extend to a position adjacent to the distal end portion 38 but not fully to the distal end of the inner catheter 14 as illustrated in FIG. 6 by the absence of the fourth lumen 52 adjacent to the distal end of the inner catheter 14. For example, a short distal segment of the fourth lumen 52 may be filled in with polymer material adjacent to the distal end of the inner catheter 14.


Returning to FIG. 4, the inner catheter 14 may also include a guidewire extension tube 62 that extends distally from the distal end portion 38. A nose cone 64 is attached to the guidewire extension tube 62. The nose cone 64 generally is designed to have an atraumatic shape. The nose cone 64 may also include a ridge or ledge 66 that is configured to abut the distal tip 24 of the outer sheath 12 during delivery of the implant 16.



FIG. 7 illustrates some of the additional components of the system 10 and the implant 16. For example, here it can be seen that the implant 16 includes a plurality of valve leaflets 68 (e.g., bovine pericardial) which are secured to a cylindrical braid 70 at a post or commissure post 72, for example at the commissure portions of the leaflets 68. In this example, the implant 16 includes three leaflets 68 secured to the braid 70 with three posts 72. The leaflets 68 may also be secured to the base or “distal end” of the braid 70. The posts 72, in turn, may be secured to the braid 70 (e.g., along the interior of the braid 70) with sutures or other suitable mechanisms. Positioned adjacent to (e.g., longitudinally spaced from and aligned with) the posts 72 are a plurality of buckles 76, which may also be sutured to the braid 70 (e.g., along the interior of the braid 70). In this example, one buckle 76 is attached to the braid 70 adjacent to each of the three posts 72. Accordingly, the braid 70 has a total of three buckles 76 and three posts 72 attached thereto. Other embodiments are contemplated where fewer or more buckles 76 and posts 72 may be utilized. A seal 74 (shown in cross-section) may be disposed about the braid 70 and, as the name suggests, may help to seal the implant 16 within a target implant site or area of interest.


Attachment between the implant 16 and the inner catheter 14 (and/or outer sheath 12) may be effected through the use of a three finger coupler 78. It will be appreciated that the coupler 78 is merely an example, as other couplers may include additional components not shown with the coupler 78. The coupler 78 may generally include a cylindrical base (not shown) that is attached to the inner catheter 14 (e.g., disposed about and attached to the reduced outer diameter section 42). Projecting distally from the base are three fingers that are each configured to engage with the implant 16 at the posts 72 and the buckles 76. A collar 80 may further assist in holding together these structures. A guide 82 may be disposed over each of the fingers and may serve to keep the fingers of the coupler 78 associated with push-pull rods 84 extending adjacent to the coupler 78. Finally, a pin release assembly 86 may be a linking structure that keeps the posts 72, the buckles 76, and the push-pull rods 84 associated with one another. The pin release assembly 86 includes a plurality of individual pins 88 that may be joined together via a coiled connection 90 and held to a pin release mandrel 92 with a ferrule 94.


During delivery, the implant 16 is secured at the distal end of the inner catheter 14 by virtue of the association of the fingers of the coupler 78 being coupled with a projecting proximal end of the buckles 76 (and being held in place with the collar 80 disposed over the connection) and by virtue of the pins 88 securing together the push-pull rods 84 and the posts 72. When the implant 16 is advanced within the anatomy to the desired location, the outer sheath 12 may be withdrawn (e.g., moved proximally relative to the inner catheter 14) to expose the implant 16. Then, the push-pull rods 84 can be used to expand and “lock” the implant 16 in the expanded or deployed configuration by proximally retracting the push-pull rods 84 to pull the posts 72 into engagement with the buckles 76. Finally, the pins 88 can be removed, thereby uncoupling the push-pull rods 84 from the posts 72, which allows the implant 16 to be released from the system 10 and deployed in the anatomy.



FIG. 8 through FIG. 11 illustrate the locking system utilized with the system 10. For simplicity purposes, only one of the three fingers of the coupler 78, only one of the three push-pull rods 84, and only one of the posts 72 of the example system 10 are shown (and the implant 16 is not shown). As seen in FIG. 8, the push-pull rod 84 extends through the guide 82 adjacent to the fingers of the coupler 78, through the collar 80, through the buckle 76, and into a hollow t-shaped bar portion 96 of the post 72. The distal end of the push-pull rod 84 may include an opening or aperture (not shown) that can be aligned with an opening 98 of the t-shaped bar portion 96. When so aligned, the pin 88 can be looped through the opening 98 and the opening of the push-pull rod 84. This secures the push-pull rod 84 to the post 72 and forms a configuration of these structures that can be utilized during delivery of the implant 16. As can be appreciated, the proximal end of the post 72 and the distal end of the buckle 76 are longitudinally separated and, accordingly, the implant 16 is in an elongated and generally low-profile configuration suitable for delivery.


When the implant 16 reaches the intended target site within the anatomy, a clinician can proximally retract the push-pull rod 84, thereby moving the proximal ends of the posts 72 toward the distal ends of the buckles 76 in order to expand the implant 16. Ultimately, the push-pull rod 84 can be retracted sufficiently far enough to lock the post 72 with the buckle 76 so as to lock implant in an expanded configuration suitable for implantation within the anatomy. FIG. 9 illustrates the push-pull rod 84 proximally retracted. In doing so, the post 72 is brought into contact with the buckle 76. More particularly, a raised, generally transversely-oriented ridge 100 on the t-shaped bar portion 96 may be pulled proximally past the buckle 76 so that the post 72 is secured and held in place by the buckle 76. At this point, it is possible to urge the push-pull rods 84 distally to “unlock” the implant 16, thereby allowing for repositioning and/or retraction. Alternatively, if a clinician is satisfied with the positioning and/or locking of the implant 16 (e.g., after visualization of the implant 16 via a suitable imaging technique), the pins 88 may be pulled (e.g., removed from the openings 98 and the openings in the push-pull rods 84) to uncouple the push-pull rods 84 from the posts 72 as shown in FIG. 10. Further retraction of the push-pull rods 84 causes a longitudinally-oriented ridge 102 on the push-pull rods 84 to engage the collar 80 and causes the collar 80 to slide proximally along the fingers of the coupler 78. In doing so, a forked end 104 of the fingers, which has a groove 106 formed therein, is exposed and can be uncoupled from a rail 108, which has a projection 110 formed thereon that is configured to mate with the groove 106, as shown in FIG. 11. Thereafter, the system 10 can be removed from the anatomy, leaving behind the expanded and deployed the implant 16.


In some cases, the system 10 may include sheathing aids that facilitate sheathing the implant 16 (FIG. 1) into the outer sheath 12 (FIG. 1). In some instances, sheathing aids may also assist in the initial sheathing of the implant 16 (e.g. removing the implant 16 from a packaging container such as a bottle and pulling the implant 16 into the outer sheath 12) and in re-sheathing the implant 16 during repositioning and/or retraction of the implant 16 within the area of interest. In some cases, as will be discussed, sheathing aids may also be adapted or otherwise configured to aid in deploying the implant 16, such as by limiting distal advancement of the implant 16 relative to an native valve annulus. FIG. 12 through FIG. 14 provide views of a system 210 that includes sheathing aids that are adapted both to assist in sheathing or re-sheathing the valve 16, but to also limit distal advancement.


As seen in FIG. 12, the system 210 includes an outer member 212 and an inner member 214. In some instances, the outer member 212 may be considered as representing the outer sheath 12 while the inner member 214 may be considered as representing the inner catheter 14, for example. A plurality of looped sheathing aids 216 may be seen as extending distally from the inner member 214. A total of three looped sheathing aids 216 are shown, although in some cases it is contemplated that the system 210 may have only one or two looped sheathing aids 216. In some cases, depending on peculiarities of a patient's anatomy, or what type of valve is being implanted, the system 210 may include more than three looped sheathing aids 216.


In some cases, each of the looped sheathing aids 216 may be considered as being fixed in place relative to the inner member 214. In some instances, it is contemplated that at least some of the looped sheathing aids 216 may instead be moveably secured relative to the inner member 214 such that the looped sheathing aids 216, or at least some thereof, may be moved distally or proximally in order to control the relative position of each of the looped sheathing aids 216.


In some cases, each of the looped sheathing aids 216 may be considered as having a first leg 218, a second leg 220 and a distal petal 222 that is disposed between the first leg 218 and the second leg 220. In some cases, each of the looped sheathing aids 216 may be formed from a wire that is bent into the shape shown, having the first leg 218, the second leg 220 and the intervening distal petal 222. In some cases, each of the looped sheathing aids 216 may be formed by laser cutting the first leg 218, the second leg 220 and the distal petal 222 from a piece of metal.


In some instances, at least some of the looped sheathing aids 216 may be adapted to be manually adjusted in shape prior to use. This may include manually bending one or more of the looped sheathing aids 216, or portions thereof, to more accurately accommodate the particular features of an individual patient's cardiac anatomy, for example. In some cases, this may also or alternatively include changing a length of the first leg 218 and/or the second leg 220 of at least some of the looped sheathing aids 216. In some cases, the looped sheathing aids 216 may be formed of a stainless steel.


In some instances, at least some of the looped sheathing aids 216 may be biased into a configuration in which each distal petal 222 is positioned to engage the tissue adjacent a native valve annulus and are further adapted to deflect away from the biased shape for advancing the delivery system into a position in which the implant 16 is positioned proximate the native valve annulus. In some cases, at least some of the looped sheathing aids 216 may be formed of a shape memory material. In some instances, at least some of the looped sheathing aids 216 may be formed of a nickel titanium alloy such as NITINOL®. The biased shape, and deflecting therefrom, may be seen, in part, in FIG. 13, in which the outer member 212 has been advanced distally, causing the looped sheathing aids 216 to deflect inwardly relative to the biased position shown for example in FIG. 12. In FIG. 14, the outer member 212 has been advanced further in a distal direction, causing the looped sheathing aids 216 to further deflect inwardly from the biased position shown in FIG. 12.


In some cases, the implant 16 may be an implantable aortic valve. FIG. 15 is a schematic top view of a native aortic valve AV. This view may be considered as having sliced through the aorta above the aortic valve AV, looking downward at the native leaflets NL. Blood flow through the aortic valve AV comes up through the aortic valve AV, from the left ventricle. As shown in FIG. 15, the native leaflets NL are shown in a closed position, in which no blood is permitted to flow through. It will be appreciated that each of the native leaflets NL are positioned adjacent a corresponding sinus of Valsalva SV.


By comparing the configuration of the looped sheathing aids 216, particularly as shown in FIG. 12, with the anatomy shown in FIG. 15, it can be seen that each of the three looped sheathing aids 216, or more particularly, the three distal petals 222 of the three looped sheathing aids 216, may fit into the corresponding sinus of Valsalva SV. As can be imagined, the three distal petals 222 fit into each sinus of Valsalva SV, and are constrained against further distal movement because the three distal petals 222 are in contact with each sinus of Valsalva SV. The three distal petals 222 are also constrained against further radial movement by the wall of the aorta. Accordingly, by controlling the size and shape of the three looped sheathing aids 216, relative to the anatomy of a particular patient's aorta, the looped sheathing aids 216 enable control of the depth at which the implant 16 is implanted relative to the native valve.


In some cases, as shown in FIG. 16, the inner catheter 14 includes an alternate coupler 178 previously discussed relative to FIG. 7 (e.g. 78). While the coupler 178 includes a total of three fingers 180 that are similar to the fingers shown in FIG. 7, the coupler 178 also includes a total of three looped sheathing aids 216, as described with respect to FIG. 12. As discussed with respect to FIG. 7, each of the fingers 180 may be configured to engage with the implant 16 at posts 72 and buckles 76 (FIG. 7). As discussed, each of the looped sheathing aids 216 include the first leg 218, the second leg 220 and the distal petal 222 disposed therebetween. In some cases an actuation member 200 may extend distally through the inner catheter 14 and the elongate member 190.


In some cases, the coupler 178 includes an elongate member 190 that extends between a distal end 192 of the inner catheter 14 to where the fingers 180 start. The elongate member 190 may be considered as having a proximal region 190a and a distal region 190b. The elongate member 190 may, in some instances, include several windows 194 that are cut into the elongate member 190 for aiding in bonding the elongate member 190 to the inner catheter 14. In some cases, the coupler 178 may be laser cut from a single piece of metal, with the elongate member 190 and each of the fingers 180 all cut from that single piece of metal. In some cases, therefore, the coupler 178 may be considered as being integrally formed. Alternatively, in some cases, the fingers 180 may instead be welded or soldered to the elongate member 190. In some cases, the flexibility of the elongate member 190 may aid in aligning the implant 16 with the native annulus, for example. In some cases, this may also reduce the forces necessary to forward load the implant 16 during deployment. In some cases, the looped sheathing aids 216 extend distally from a position interior to the coupler 178.


In some cases, the three fingers 180 are each radially spaced about 120 degrees apart from one another. Similarly, the three looped sheathing aids 216 are each radially spaced about 120 degrees apart from one another, and in some cases each looped sheathing aids 216 may be equally spaced between adjacent fingers 180. In some cases, then, there is a finger 180 or a looped sheathing aids 216 radially spaced about 60 degrees apart from a neighboring finger 180 or a neighboring looped sheathing aids 216. While a total of three looped sheathing aids 216 are illustrated, it will be appreciated that in some cases there may be more than three looped sheathing aids 216. While the three looped sheathing aids 216 are shown as being equally spaced apart, this is not required in all cases. In some cases, one or more of the looped sheathing aids 216 may vary in length.



FIG. 17 is similar to FIG. 7, but illustrates the position of the looped sheathing aids 216 relative to the implant 16. In this view, two looped sheathing aids 216 are easily seen, as a third looped sheathing aid 216 is positioned behind (in the illustrated orientation) the implant 16. As can be seen, the looped sheathing aids 216 extend distally from within the outer sheath 12. In some cases, the looped sheathing aids 216 may extend from the inner catheter 14, but this is not required in all cases. The looped sheathing aids 216 extend about an exterior of the implant 16, such that the looped sheathing aids 216 are able to help guide the implant 16 back into the outer sheath 12 for sheathing or re-sheathing, in addition to the previous discussion regarding the utility of the looped sheathing aids 216 in guiding depth placement of the implant 16. In some cases, the looped sheathing aids 216, by virtue of their interaction with each corresponding sinus of Valsalva (SV), also help to center the implant 16 relative to the native valve.


The materials that can be used for the various components of the system 10 (and/or other systems disclosed herein) and the various tubular members disclosed herein may include those commonly associated with medical devices. For simplicity purposes, the following discussion makes reference to the outer sheath 12 and/or the inner catheter 14. However, this is not intended to limit the devices and methods described herein, as the discussion may be applied to other similar tubular members and/or components of tubular members or devices disclosed herein.


The outer sheath 12 and/or the inner catheter 14 may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable material. The coupler 178, 278 may be formed of a metal. Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; combinations thereof; and the like; or any other suitable material.


As alluded to herein, within the family of commercially available nickel-titanium or nitinol alloys, is a category designated “linear elastic” or “non-super-elastic” which, although may be similar in chemistry to conventional shape memory and super elastic varieties, may exhibit distinct and useful mechanical properties. Linear elastic and/or non-super-elastic nitinol may be distinguished from super elastic nitinol in that the linear elastic and/or non-super-elastic nitinol does not display a substantial “superelastic plateau” or “flag region” in its stress/strain curve like super elastic nitinol does. Instead, in the linear elastic and/or non-super-elastic nitinol, as recoverable strain increases, the stress continues to increase in a substantially linear, or a somewhat, but not necessarily entirely linear relationship until plastic deformation begins or at least in a relationship that is more linear that the super elastic plateau and/or flag region that may be seen with super elastic nitinol. Thus, for the purposes of this disclosure linear elastic and/or non-super-elastic nitinol may also be termed “substantially” linear elastic and/or non-super-elastic nitinol.


In some cases, linear elastic and/or non-super-elastic nitinol may also be distinguishable from super elastic nitinol in that linear elastic and/or non-super-elastic nitinol may accept up to about 2-5% strain while remaining substantially elastic (e.g., before plastically deforming) whereas super elastic nitinol may accept up to about 8% strain before plastically deforming. Both of these materials can be distinguished from other linear elastic materials such as stainless steel (that can also can be distinguished based on its composition), which may accept only about 0.2 to 0.44 percent strain before plastically deforming.


In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy is an alloy that does not show any martensite/austenite phase changes that are detectable by differential scanning calorimetry (DSC) and dynamic metal thermal analysis (DMTA) analysis over a large temperature range. For example, in some embodiments, there may be no martensite/austenite phase changes detectable by DSC and DMTA analysis in the range of about −60 degrees Celsius (° C.) to about 120° C. in the linear elastic and/or non-super-elastic nickel-titanium alloy. The mechanical bending properties of such material may therefore be generally inert to the effect of temperature over this very broad range of temperature. In some embodiments, the mechanical bending properties of the linear elastic and/or non-super-elastic nickel-titanium alloy at ambient or room temperature are substantially the same as the mechanical properties at body temperature, for example, in that they do not display a super-elastic plateau and/or flag region. In other words, across a broad temperature range, the linear elastic and/or non-super-elastic nickel-titanium alloy maintains its linear elastic and/or non-super-elastic characteristics and/or properties.


In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy may be in the range of about 50 to about 60 weight percent nickel, with the remainder being essentially titanium. In some embodiments, the composition is in the range of about 54 to about 57 weight percent nickel. One example of a suitable nickel-titanium alloy is FHP-NT alloy commercially available from Furukawa Techno Material Co. of Kanagawa, Japan. Some examples of nickel titanium alloys are disclosed in U.S. Pat. Nos. 5,238,004 and 6,508,803, which are incorporated herein by reference. Other suitable materials may include ULTANIUM™ (available from Neo-Metrics) and GUM METAL™ (available from Toyota). In some other embodiments, a superelastic alloy, for example a superelastic nitinol can be used to achieve desired properties.


In at least some embodiments, portions or all of the outer sheath 12 and the inner catheter 14 may also be doped with, made of, or otherwise include a radiopaque material. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique during a medical procedure. This relatively bright image aids the user of the system 10 in determining its location. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like. Additionally, other radiopaque marker bands and/or coils may also be incorporated into the design of the system 10 to achieve the same result.


In some embodiments, a degree of Magnetic Resonance Imaging (MM) compatibility is imparted into the system 10. For example, the outer sheath 12 and the inner catheter 14, or portions thereof, may be made of a material that does not substantially distort the image and create substantial artifacts (i.e., gaps in the image). Certain ferromagnetic materials, for example, may not be suitable because they may create artifacts in an MRI image. The outer sheath 12 and inner catheter 14, or portions thereof, may also be made from a material that the MRI machine can image. Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nitinol, and the like, and others.


A sheath or covering (not shown) may be disposed over portions or all of the outer sheath 12 and the inner catheter 14 that may define a generally smooth outer surface for the system 10. In other embodiments, however, such a sheath or covering may be absent from a portion of all of the system 10, such that the outer sheath 12 and the inner catheter 14 may form an outer surface. The sheath may be made from a polymer or other suitable material. Some examples of suitable polymers may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN® available from DuPont), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), Marlex high-density polyethylene, Marlex low-density polyethylene, linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID® available from EMS American Grilon), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, ionomers, biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments the sheath can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6 percent LCP.


In some embodiments, the exterior surface of the system 10 (including, for example, the exterior surface of the outer sheath 12 and the inner catheter 14) may be sandblasted, beadblasted, sodium bicarbonate-blasted, electropolished, etc. In these as well as in some other embodiments, a coating, for example a lubricious, a hydrophilic, a protective, or other type of coating may be applied over portions or all of the sheath, or in embodiments without a sheath over portion of the outer sheath 12 and the inner catheter 14, or other portions of the system 10. Alternatively, the sheath may comprise a lubricious, hydrophilic, protective, or other type of coating. Hydrophobic coatings such as fluoropolymers provide a dry lubricity which improves device handling and device exchanges. Lubricious coatings improve steerability and improve lesion crossing capability. Suitable lubricious polymers are well known in the art and may include silicone and the like, hydrophilic polymers such as high-density polyethylene (HDPE), polytetrafluoroethylene (PTFE), polyarylene oxides, polyvinylpyrolidones, polyvinylalcohols, hydroxy alkyl cellulosics, algins, saccharides, caprolactones, and the like, and mixtures and combinations thereof. Hydrophilic polymers may be blended among themselves or with formulated amounts of water insoluble compounds (including some polymers) to yield coatings with suitable lubricity, bonding, and solubility. Some other examples of such coatings and materials and methods used to create such coatings can be found in U.S. Pat. Nos. 6,139,510 and 5,772,609, which are incorporated herein by reference.


The coating and/or sheath may be formed, for example, by coating, extrusion, co-extrusion, interrupted layer co-extrusion (ILC), or fusing several segments end-to-end. The layer may have a uniform stiffness or a gradual reduction in stiffness from the proximal end to the distal end thereof. The gradual reduction in stiffness may be continuous as by ILC or may be stepped as by fusing together separate extruded tubular segments. The outer layer may be impregnated with a radiopaque filler material to facilitate radiographic visualization. Those skilled in the art will recognize that these materials can vary widely without deviating from the scope of the present invention.


It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the invention. This may include, to the extent that it is appropriate, the use of any of the features of one example embodiment being used in other embodiments. The invention's scope is, of course, defined in the language in which the appended claims are expressed.

Claims
  • 1. A delivery system for delivering an implantable heart valve, the delivery system comprising: an outer shaft having an outer shaft lumen extending therethrough;an inner shaft slidingly disposable within the outer shaft lumen, the inner shaft including a distal end region and defining an inner shaft lumen therethrough;a plurality of fingers extending distally relative to the distal end region of the inner shaft, the plurality of fingers adapted to releasably engage an implantable heart valve; anda plurality of looped sheathing aids extending distally from the distal end region of the inner shaft lumen and adapted to guide the implantable heart valve back into the outer shaft lumen when the implantable heart valve is pulled back into the outer shaft lumen;wherein each of the plurality of looped sheathing aids includes a distal petal adapted to engage tissue adjacent a native valve annulus to limit distal advancement of the implantable heart valve and to center the implantable heart valve relative to a native valve during deployment of the implantable heart valve.
  • 2. The delivery system of claim 1, wherein each of the plurality of looped sheathing aids comprises a length of wire shaped into a first leg and a second leg, with the distal petal therebetween.
  • 3. The delivery system of claim 1, wherein each of the plurality of looped sheathing aids is laser cut from a piece of metal to include a first leg, a second leg, with the distal petal therebetween.
  • 4. The delivery system of claim 1, wherein each of the plurality of looped sheathing aids is adapted to be manually adjusted in shape prior to use.
  • 5. The delivery system of claim 4, wherein each of the plurality of looped sheathing aids comprises stainless steel.
  • 6. The delivery system of claim 1, wherein each of the plurality of looped sheathing aids is biased into a configuration in which each distal petal is positioned to engage the tissue adjacent a native valve annulus and are further adapted to deflect away from the biased configuration for advancing the delivery system into a position in which the implantable heart valve is positioned proximate the native valve annulus.
  • 7. The delivery system of claim 6, wherein each of the plurality of looped sheathing aids comprises a shape memory material.
  • 8. The delivery system of claim 6, wherein each of the plurality of looped sheathing aids comprises a nickel titanium alloy.
  • 9. The delivery system of claim 1, wherein the implantable heart valve comprises an implantable aortic valve, and each of the plurality of looped sheathing aids comprises a distal petal adapted to engage a sinus of Valsalva adjacent a native aortic annulus.
  • 10. The delivery system of claim 1, further comprising a coupler secured to the distal end region and defining a coupler lumen extending therethrough in coaxial alignment with the inner shaft lumen, where: the plurality of fingers extends distally from the coupler; andthe plurality of looped sheathing aids extends distally from within the coupler lumen.
  • 11. The delivery system of claim 10, wherein the plurality of fingers is part of a tubular member forming the coupler.
  • 12. A delivery system for delivering an implantable heart valve, the delivery system comprising: an outer sheath adapted to reversibly house the implantable heart valve therein;an inner member slidingly disposed within the outer sheath and defining an inner member lumen, the inner member adapted to releasably secure the implantable heart valve and to advance the implantable heart valve from a position within the outer sheath to a position distal of the outer sheath; andthree looped sheathing aids extending distally through the inner member lumen, each of the three looped sheathing aids including a distal petal that is adapted to engage tissue proximate a native valve annulus to limit distal travel of the delivery system and to center the implantable heart valve relative to a native valve during deployment of the implantable heart valve;wherein the three looped sheathing aids are adapted to guide the implantable heart valve back into the outer sheath when the implantable heart valve is pulled back into the outer sheath.
  • 13. The delivery system of claim 12, wherein the inner member comprises three fingers that extend distally from the inner member and are adapted to releasably engage the implantable heart valve.
  • 14. The delivery system of claim 12, wherein each of the three looped sheathing aids is biased into a configuration in which each distal petal is positioned to engage the tissue adjacent a native valve annulus and is further adapted to deflect away from the biased shape for advancing the delivery system into a position in which the implantable heart valve is positioned proximate the native valve annulus.
  • 15. The delivery system of claim 12, wherein each of the three looped sheathing aids comprises a shape memory material.
  • 16. The delivery system of claim 12, wherein each of the three looped sheathing aids comprises a nickel titanium alloy.
  • 17. The delivery system of claim 12, wherein the implantable heart valve comprises an implantable aortic valve, and each of the three looped sheathing aids comprises a distal petal adapted to engage a sinus of Valsalva adjacent a native aortic annulus.
  • 18. A delivery system for delivering an implantable aortic valve, the delivery system comprising: an outer sheath adapted to reversibly house the implantable aortic valve therein;an inner member slidingly disposed within the outer sheath and defining an inner member lumen, the inner member adapted to releasably secure the implantable aortic valve and to advance the implantable aortic valve from a position within the outer sheath to a position distal of the outer sheath; andthree looped sheathing aids extending distally through the inner member lumen, each of the three looped sheathing aids includes a distal petal that is adapted to engage a sinus of Valsalva adjacent a native aortic annulus in order to limit distal travel of the delivery system and to center the implantable aortic valve relative to a native valve.
  • 19. The delivery system of claim 18, wherein the three looped sheathing aids are further adapted to guide the implantable aortic valve back into the outer sheath when the implantable aortic valve is pulled back into the outer sheath.
  • 20. The delivery system of claim 18, wherein each of the three looped sheathing aids is formed to include a first leg and a second leg with the distal petal disposed therebetween.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority under 35 U.S.C. § 119 to U.S. Provisional Application Ser. No. 62/627,331, filed Feb. 7, 2018, the entirety of which is incorporated herein by reference.

US Referenced Citations (909)
Number Name Date Kind
15192 Peale Jun 1856 A
2682057 Lord Jun 1954 A
2701559 Cooper Feb 1955 A
2832078 Williams Apr 1958 A
3029819 Starks Apr 1962 A
3099016 Lowell Jul 1963 A
3113586 Edmark Dec 1963 A
3130418 Head et al. Apr 1964 A
3143742 Cromie Aug 1964 A
3221006 Moore et al. Nov 1965 A
3334629 Cohn Aug 1967 A
3365728 Edwards et al. Jan 1968 A
3367364 Cruz et al. Feb 1968 A
3409013 Henry Nov 1968 A
3445916 Schulte May 1969 A
3540431 Mobin-Uddin Nov 1970 A
3548417 Kischer et al. Dec 1970 A
3570014 Hancock Mar 1971 A
3587115 Shiley Jun 1971 A
3592184 Watkins et al. Jul 1971 A
3628535 Ostrowsky et al. Dec 1971 A
3642004 Osthagen et al. Feb 1972 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Goodenough et al. Feb 1973 A
3725961 Magovem et al. Apr 1973 A
3755823 Hancock Sep 1973 A
3795246 Sturgeon Mar 1974 A
3839741 Haller Oct 1974 A
3868956 Alfidi et al. Mar 1975 A
3874388 King et al. Apr 1975 A
3983581 Angell et al. Oct 1976 A
3997923 Possis Dec 1976 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4084268 Ionescu et al. Apr 1978 A
4106129 Carpentier et al. Aug 1978 A
4222126 Boretos et al. Sep 1980 A
4233690 Akins Nov 1980 A
4265694 Boretos et al. May 1981 A
4291420 Reul Sep 1981 A
4297749 Davis et al. Nov 1981 A
4323358 Lentz et al. Apr 1982 A
4326306 Poler Apr 1982 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4406022 Roy Sep 1983 A
4423809 Mazzocco Jan 1984 A
4425908 Simon Jan 1984 A
4470157 Love Sep 1984 A
4484579 Meno et al. Nov 1984 A
4501030 Lane Feb 1985 A
4531943 Tassel et al. Jul 1985 A
4535483 Klawitter et al. Aug 1985 A
4574803 Storz Mar 1986 A
4580568 Gianturco Apr 1986 A
4592340 Boyles Jun 1986 A
4602911 Ahmadi et al. Jul 1986 A
4605407 Black et al. Aug 1986 A
4610688 Silvestrini et al. Sep 1986 A
4612011 Kautzky Sep 1986 A
4617932 Komberg Oct 1986 A
4643732 Pietsch et al. Feb 1987 A
4647283 Carpentier et al. Mar 1987 A
4648881 Carpentier et al. Mar 1987 A
4655218 Kulik et al. Apr 1987 A
4655771 Wallsten et al. Apr 1987 A
4662885 DiPisa May 1987 A
4665906 Jervis May 1987 A
4680031 Alonso Jul 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4705516 Barone et al. Nov 1987 A
4710192 Liotta et al. Dec 1987 A
4733665 Palmaz et al. Mar 1988 A
4755181 Igoe Jul 1988 A
4759758 Gabbay Jul 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4819751 Shimada et al. Apr 1989 A
4829990 Thuroff et al. May 1989 A
4834755 Silvestrini et al. May 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4865600 Carpentier et al. Sep 1989 A
4872874 Taheri Oct 1989 A
4873978 Ginsburg Oct 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4885005 Nashef et al. Dec 1989 A
4909252 Goldberger Mar 1990 A
4917102 Miller et al. Apr 1990 A
4922905 Strecker May 1990 A
4927426 Dretler May 1990 A
4954126 Wallsten Sep 1990 A
4966604 Reiss Oct 1990 A
4969890 Sugita et al. Nov 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5002556 Ishida et al. Mar 1991 A
5002559 Tower Mar 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5064435 Porter Nov 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5122154 Rhodes Jun 1992 A
5132473 Furutaka et al. Jul 1992 A
5141494 Danforth et al. Aug 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5159937 Tremulis Nov 1992 A
5161547 Tower Nov 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5209741 Spaeth May 1993 A
5215541 Nashef et al. Jun 1993 A
5217481 Barbara Jun 1993 A
5217483 Tower Jun 1993 A
5238004 Sahatjian et al. Aug 1993 A
5258023 Reger Nov 1993 A
5258042 Mehta Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5332402 Teitelbaum Jul 1994 A
5336258 Quintero et al. Aug 1994 A
5350398 Pavcnik et al. Sep 1994 A
5360444 Kusuhara Nov 1994 A
5370685 Stevens Dec 1994 A
5389106 Tower Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5409019 Wilk Apr 1995 A
5411552 Andersen et al. May 1995 A
5425739 Jessen Jun 1995 A
5425762 Muller Jun 1995 A
5431676 Dubrul et al. Jul 1995 A
5443446 Shturman Aug 1995 A
5443449 Buelna Aug 1995 A
5443477 Marin et al. Aug 1995 A
5443495 Buscemi et al. Aug 1995 A
5443499 Schmitt Aug 1995 A
5469868 Reger Nov 1995 A
5476506 Lunn Dec 1995 A
5476510 Eberhardt et al. Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5480424 Cox Jan 1996 A
5489297 Duran Feb 1996 A
5500014 Quijano et al. Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5522881 Lentz Jun 1996 A
5534007 Germain et al. Jul 1996 A
5545133 Bums et al. Aug 1996 A
5545209 Roberts et al. Aug 1996 A
5545211 An et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554185 Block et al. Sep 1996 A
5571175 Vanney et al. Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5575818 Pinchuk Nov 1996 A
5591185 Kilmer et al. Jan 1997 A
5591195 Taheri et al. Jan 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5628784 Strecker May 1997 A
5645559 Hachtman et al. Jul 1997 A
5653745 Trescony et al. Aug 1997 A
5662671 Barbut et al. Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5681345 Euteneuer Oct 1997 A
5693083 Baker et al. Dec 1997 A
5693088 Lazarus Dec 1997 A
5693310 Gries et al. Dec 1997 A
5695498 Tower Dec 1997 A
5709713 Evans et al. Jan 1998 A
5713951 Garrison et al. Feb 1998 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson et al. Feb 1998 A
5716417 Girard et al. Feb 1998 A
5720391 Dohm et al. Feb 1998 A
5725549 Lam Mar 1998 A
5728068 Leone et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5735842 Krueger et al. Apr 1998 A
5749890 Shaknovich May 1998 A
5755783 Stobie et al. May 1998 A
5756476 Epstein et al. May 1998 A
5769812 Stevens et al. Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5772609 Nguyen et al. Jun 1998 A
5776188 Shepherd et al. Jul 1998 A
5782904 White et al. Jul 1998 A
5800456 Maeda et al. Sep 1998 A
5800531 Cosgrove et al. Sep 1998 A
5807405 Vanney et al. Sep 1998 A
5817126 Imran Oct 1998 A
5824037 Fogarty et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824043 Cottone Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5824055 Spiridigliozzi et al. Oct 1998 A
5824056 Rosenberg Oct 1998 A
5824064 Taheri Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5843158 Lenker et al. Dec 1998 A
5843161 Solovay Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5860966 Tower Jan 1999 A
5860996 Urban et al. Jan 1999 A
5861024 Rashidi Jan 1999 A
5861028 Angell Jan 1999 A
5868783 Tower Feb 1999 A
5876419 Carpenter et al. Mar 1999 A
5876448 Thompson et al. Mar 1999 A
5885228 Rosenman et al. Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5891191 Stinson Apr 1999 A
5895399 Barbut et al. Apr 1999 A
5906619 Olson et al. May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5910154 Tsugita et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5944738 Amplatz et al. Aug 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968070 Bley et al. Oct 1999 A
5984957 Laptewicz et al. Nov 1999 A
5984959 Robertson et al. Nov 1999 A
5993469 McKenzie et al. Nov 1999 A
5997557 Barbut et al. Dec 1999 A
6010522 Barbut et al. Jan 2000 A
6015431 Thornton et al. Jan 2000 A
6022370 Tower Feb 2000 A
6027520 Tsugita et al. Feb 2000 A
6027525 Suh et al. Feb 2000 A
6042598 Tsugita et al. Mar 2000 A
6042607 Williamson et al. Mar 2000 A
6051014 Jang Apr 2000 A
6059827 Fenton May 2000 A
6074418 Buchanan et al. Jun 2000 A
6093203 Uflacker Jul 2000 A
6096074 Pedros Aug 2000 A
6110198 Fogarty et al. Aug 2000 A
6123723 Konya et al. Sep 2000 A
6132473 Williams et al. Oct 2000 A
6139510 Palermo Oct 2000 A
6142987 Tsugita Nov 2000 A
6146366 Schachar Nov 2000 A
6162245 Jayaraman Dec 2000 A
6165200 Tsugita et al. Dec 2000 A
6165209 Patterson et al. Dec 2000 A
6168579 Tsugita Jan 2001 B1
6168614 Andersen et al. Jan 2001 B1
6171327 Daniel et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6187016 Hedges et al. Feb 2001 B1
6197053 Cosgrove et al. Mar 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6206911 Milo Mar 2001 B1
6214036 Letendre et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6221100 Strecker Apr 2001 B1
6231544 Tsugita et al. May 2001 B1
6231551 Barbut May 2001 B1
6241757 An et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6251135 Stinson et al. Jun 2001 B1
6258114 Konya et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6258129 Dybdal et al. Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6270513 Tsugita et al. Aug 2001 B1
6277555 Duran et al. Aug 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6306164 Kujawski Oct 2001 B1
6309417 Spence et al. Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6319281 Patel Nov 2001 B1
6327772 Zadno-Azizi et al. Dec 2001 B1
6336934 Gilson et al. Jan 2002 B1
6336937 Vonesh et al. Jan 2002 B1
6338735 Stevens Jan 2002 B1
6346116 Brooks et al. Feb 2002 B1
6348063 Yassour et al. Feb 2002 B1
6352554 Paulis Mar 2002 B2
6352708 Duran et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6363938 Saadat et al. Apr 2002 B2
6364895 Greenhalgh Apr 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6387122 Cragg May 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6402736 Brown et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6416510 Altman et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6475239 Campbell et al. Nov 2002 B1
6482228 Norred Nov 2002 B1
6485501 Green Nov 2002 B1
6485502 Michael et al. Nov 2002 B2
6488704 Connelly et al. Dec 2002 B1
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6508803 Horikawa et al. Jan 2003 B1
6508833 Pavcnik et al. Jan 2003 B2
6527800 McGuckin et al. Mar 2003 B1
6530949 Konya et al. Mar 2003 B2
6530952 Vesely Mar 2003 B2
6537297 Tsugita et al. Mar 2003 B2
6540768 Diaz et al. Apr 2003 B1
6540782 Snyders Apr 2003 B1
6562058 Seguin et al. May 2003 B2
6569196 Vesely May 2003 B1
6572643 Gharibadeh Jun 2003 B1
6585766 Huynh et al. Jul 2003 B1
6592546 Barbut et al. Jul 2003 B1
6592614 Lenker et al. Jul 2003 B2
6605112 Moll et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6616682 Joergensen et al. Sep 2003 B2
6622604 Chouinard et al. Sep 2003 B1
6623518 Thompson et al. Sep 2003 B2
6623521 Steinke et al. Sep 2003 B2
6626938 Butaric et al. Sep 2003 B1
6632243 Zadno-Azizi et al. Oct 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6635079 Unsworth et al. Oct 2003 B2
6635080 Lauterjung et al. Oct 2003 B1
6652571 White et al. Nov 2003 B1
6652578 Bailey et al. Nov 2003 B2
6663588 DuBois et al. Dec 2003 B2
6663663 Kim et al. Dec 2003 B2
6663667 Dehdashtian et al. Dec 2003 B2
6669724 Park et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673109 Cox Jan 2004 B2
6676668 Mercereau et al. Jan 2004 B2
6676692 Rabkin et al. Jan 2004 B2
6676698 McGuckin et al. Jan 2004 B2
6682543 Barbut et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6689144 Gerberding Feb 2004 B2
6689164 Seguin Feb 2004 B1
6692512 Jang Feb 2004 B2
6695864 Macoviak et al. Feb 2004 B2
6695865 Boyle et al. Feb 2004 B2
6702851 Chinn et al. Mar 2004 B1
6712842 Gifford et al. Mar 2004 B1
6712843 Elliott Mar 2004 B2
6714842 Ito Mar 2004 B1
6719789 Cox Apr 2004 B2
6723116 Taheri Apr 2004 B2
6729356 Baker et al. May 2004 B1
6730118 Spenser et al. May 2004 B2
6730377 Wang May 2004 B2
6733525 Yang et al. May 2004 B2
6736846 Cox May 2004 B2
6752828 Thornton Jun 2004 B2
6755854 Gillick et al. Jun 2004 B2
6758855 Fulton et al. Jul 2004 B2
6764503 Ishimaru Jul 2004 B1
6764509 Chinn et al. Jul 2004 B2
6767345 Germain et al. Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6773454 Wholey et al. Aug 2004 B2
6773456 Gordon et al. Aug 2004 B1
6776791 Stallings et al. Aug 2004 B1
6786925 Schoon et al. Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6790237 Stinson Sep 2004 B2
6792979 Konya et al. Sep 2004 B2
6797002 Spence et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6814754 Greenhalgh Nov 2004 B2
6821297 Snyders Nov 2004 B2
6824041 Grieder et al. Nov 2004 B2
6830585 Artof et al. Dec 2004 B1
6837901 Rabkin et al. Jan 2005 B2
6840957 DiMatteo et al. Jan 2005 B2
6843802 Villalobos et al. Jan 2005 B1
6849085 Marton Feb 2005 B2
6863668 Gillespie et al. Mar 2005 B2
6863688 Ralph et al. Mar 2005 B2
6866650 Stevens et al. Mar 2005 B2
6866669 Buzzard et al. Mar 2005 B2
6872223 Roberts et al. Mar 2005 B2
6872226 Cali et al. Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6881220 Edwin et al. Apr 2005 B2
6887266 Williams et al. May 2005 B2
6890340 Duane May 2005 B2
6893459 Macoviak May 2005 B1
6893460 Spenser et al. May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6905743 Chen et al. Jun 2005 B1
6908481 Cribier Jun 2005 B2
6911036 Douk et al. Jun 2005 B2
6911040 Johnson et al. Jun 2005 B2
6911043 Myers et al. Jun 2005 B2
6936058 Forde et al. Aug 2005 B2
6936067 Buchanan Aug 2005 B2
6939352 Buzzard et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6953332 Kurk et al. Oct 2005 B1
6964673 Tsugita et al. Nov 2005 B2
6969395 Eskuri Nov 2005 B2
6972025 WasDyke Dec 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974474 Pavcnik et al. Dec 2005 B2
6974476 McGuckin et al. Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
6984242 Campbell et al. Jan 2006 B2
6989027 Allen et al. Jan 2006 B2
7004176 Lau Feb 2006 B2
7011681 Vesely Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7025791 Levine et al. Apr 2006 B2
7037331 Mitelberg et al. May 2006 B2
7041132 Quijano et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7097658 Dktay Aug 2006 B2
7108715 Lawrence-Brown et al. Sep 2006 B2
7122020 Mogul Oct 2006 B2
7125418 Duran et al. Oct 2006 B2
7141063 White et al. Nov 2006 B2
7147663 Berg et al. Dec 2006 B1
7166097 Barbut Jan 2007 B2
7175652 Cook et al. Feb 2007 B2
7175653 Gaber Feb 2007 B2
7175654 Bonsignore et al. Feb 2007 B2
7175656 Khairkhahan Feb 2007 B2
7189258 Johnson et al. Mar 2007 B2
7191018 Gielen et al. Mar 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7235093 Gregorich Jun 2007 B2
7252682 Seguin Aug 2007 B2
7258696 Rabkin et al. Aug 2007 B2
7261732 Justino Aug 2007 B2
7264632 Wright et al. Sep 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7276078 Spenser et al. Oct 2007 B2
7322932 Xie et al. Jan 2008 B2
7326236 Andreas et al. Feb 2008 B2
7329279 Haug et al. Feb 2008 B2
7331993 White Feb 2008 B2
7374560 Ressemann et al. May 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7381220 Macoviak et al. Jun 2008 B2
7399315 Iobbi Jul 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7470285 Nugent et al. Dec 2008 B2
7491232 Bolduc et al. Feb 2009 B2
7510574 Lê et al. Mar 2009 B2
7524330 Berreklouw Apr 2009 B2
7530995 Quijano et al. May 2009 B2
7544206 Cohn Jun 2009 B2
7622276 Cunanan et al. Nov 2009 B2
7628803 Pavcnik et al. Dec 2009 B2
7632298 Hijlkema et al. Dec 2009 B2
7641687 Chinn et al. Jan 2010 B2
7674282 Wu et al. Mar 2010 B2
7712606 Salahieh et al. May 2010 B2
7722638 Deyette et al. May 2010 B2
7722662 Steinke et al. May 2010 B2
7722666 Lafontaine May 2010 B2
7731742 Schlick et al. Jun 2010 B2
7736388 Goldfarb et al. Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7758625 Wu et al. Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7799065 Pappas Sep 2010 B2
7803185 Gabbay Sep 2010 B2
7824442 Salahieh et al. Nov 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7833262 McGuckin et al. Nov 2010 B2
7846204 Letac et al. Dec 2010 B2
7857845 Stacchino et al. Dec 2010 B2
7892292 Stack et al. Feb 2011 B2
7918880 Austin Apr 2011 B2
7938851 Olson et al. May 2011 B2
7959666 Salahieh et al. Jun 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7988724 Salahieh et al. Aug 2011 B2
8048153 Salahieh et al. Nov 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8136659 Salahieh et al. Mar 2012 B2
8157853 Laske et al. Apr 2012 B2
8172896 McNamara et al. May 2012 B2
8182528 Salahieh et al. May 2012 B2
8192351 Fishler et al. Jun 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8231670 Salahieh et al. Jul 2012 B2
8236049 Rowe et al. Aug 2012 B2
8246678 Salahieh et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8252052 Salahieh et al. Aug 2012 B2
8287584 Salahieh et al. Oct 2012 B2
8308798 Pintor et al. Nov 2012 B2
8317858 Straubinger et al. Nov 2012 B2
8323335 Rowe et al. Dec 2012 B2
8328868 Paul et al. Dec 2012 B2
8343213 Salahieh et al. Jan 2013 B2
8376865 Forster et al. Feb 2013 B2
8377117 Keidar et al. Feb 2013 B2
8398708 Meiri et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8414644 Quadri et al. Apr 2013 B2
8579962 Salahieh et al. Nov 2013 B2
8603160 Salahieh et al. Dec 2013 B2
8617236 Paul et al. Dec 2013 B2
8623074 Ryan Jan 2014 B2
8623076 Salahieh et al. Jan 2014 B2
8623078 Salahieh et al. Jan 2014 B2
8668733 Haug et al. Mar 2014 B2
8696743 Holecek et al. Apr 2014 B2
8828078 Salahieh et al. Sep 2014 B2
8840662 Salahieh et al. Sep 2014 B2
8840663 Salahieh et al. Sep 2014 B2
8858620 Salahieh et al. Oct 2014 B2
8894703 Salahieh et al. Nov 2014 B2
8951299 Paul et al. Feb 2015 B2
8992608 Haug et al. Mar 2015 B2
9005273 Salahieh et al. Apr 2015 B2
9011521 Haug et al. Apr 2015 B2
9168131 Yohanan et al. Oct 2015 B2
20010002445 Vesely May 2001 A1
20010007956 Letac et al. Jul 2001 A1
20010010017 Letac et al. Jul 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010025196 Chinn et al. Sep 2001 A1
20010027338 Greenberg Oct 2001 A1
20010032013 Marton Oct 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010041930 Globerman et al. Nov 2001 A1
20010044634 Michael et al. Nov 2001 A1
20010044652 Moore Nov 2001 A1
20010044656 Williamson et al. Nov 2001 A1
20020002396 Fulkerson Jan 2002 A1
20020010489 Grayzel et al. Jan 2002 A1
20020026233 Shaknovich Feb 2002 A1
20020029014 Jayaraman Mar 2002 A1
20020029981 Nigam Mar 2002 A1
20020032480 Spence et al. Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020042651 Liddicoat et al. Apr 2002 A1
20020052651 Myers et al. May 2002 A1
20020055767 Forde et al. May 2002 A1
20020055769 Wang May 2002 A1
20020055774 Liddicoat May 2002 A1
20020058987 Butaric et al. May 2002 A1
20020058995 Stevens May 2002 A1
20020077696 Zadno-Azizi et al. Jun 2002 A1
20020082609 Green Jun 2002 A1
20020095173 Mazzocchi et al. Jul 2002 A1
20020095209 Zadno-Azizi et al. Jul 2002 A1
20020111674 Chouinard et al. Aug 2002 A1
20020120328 Pathak et al. Aug 2002 A1
20020123802 Snyders Sep 2002 A1
20020138138 Yang Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020156522 Ivancev et al. Oct 2002 A1
20020161390 Mouw Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 MacOviak et al. Oct 2002 A1
20020165576 Boyle et al. Nov 2002 A1
20020177766 Mogul Nov 2002 A1
20020183781 Casey et al. Dec 2002 A1
20020188341 Elliott Dec 2002 A1
20020188344 Bolea et al. Dec 2002 A1
20020193871 Beyersdorf et al. Dec 2002 A1
20030014104 Cribier Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030028247 Cali Feb 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030040736 Stevens et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030040791 Oktay Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030060844 Borillo et al. Mar 2003 A1
20030069492 Abrams et al. Apr 2003 A1
20030069646 Stinson Apr 2003 A1
20030070944 Nigam Apr 2003 A1
20030074058 Sherry Apr 2003 A1
20030093145 Lawrence-Brown et al. May 2003 A1
20030100918 Duane May 2003 A1
20030100919 Hopkins et al. May 2003 A1
20030109924 Cribier Jun 2003 A1
20030109930 Bluni et al. Jun 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030125795 Pavcnik et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030135257 Taheri Jul 2003 A1
20030144732 Cosgrove et al. Jul 2003 A1
20030149475 Hyodoh et al. Aug 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030165352 Ibrahim et al. Sep 2003 A1
20030171803 Shimon Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030191516 Weldon et al. Oct 2003 A1
20030195609 Berenstein et al. Oct 2003 A1
20030199759 Richard Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030199972 Zadno-Azizi et al. Oct 2003 A1
20030204249 Letort Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030212429 Keegan et al. Nov 2003 A1
20030212452 Zadno-Azizi et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030216774 Larson Nov 2003 A1
20030225445 Derus et al. Dec 2003 A1
20030229390 Ashton et al. Dec 2003 A1
20030233117 Adams et al. Dec 2003 A1
20030236567 Elliot Dec 2003 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040033364 Spiridigliozzi et al. Feb 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040049226 Keegan et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040059409 Stenzel Mar 2004 A1
20040073198 Gilson et al. Apr 2004 A1
20040082904 Houde et al. Apr 2004 A1
20040082967 Broome et al. Apr 2004 A1
20040082989 Cook et al. Apr 2004 A1
20040087982 Eskuri May 2004 A1
20040088045 Cox May 2004 A1
20040093016 Root et al. May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040097788 Mourlas et al. May 2004 A1
20040098022 Barone May 2004 A1
20040098098 McGuckin et al. May 2004 A1
20040098099 McCullagh et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040107004 Levine et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040116951 Rosengart Jun 2004 A1
20040116999 Ledergerber Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040127936 Salahieh et al. Jul 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040133274 Webler et al. Jul 2004 A1
20040138694 Tran et al. Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040148018 Carpentier et al. Jul 2004 A1
20040148021 Cartledge et al. Jul 2004 A1
20040153094 Dunfee et al. Aug 2004 A1
20040158277 Lowe et al. Aug 2004 A1
20040167565 Beulke et al. Aug 2004 A1
20040167620 Ortiz et al. Aug 2004 A1
20040181140 Falwell et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040197695 Aono Oct 2004 A1
20040199245 Lauterjung Oct 2004 A1
20040204755 Robin Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210306 Quijano et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215331 Chew et al. Oct 2004 A1
20040215333 Duran et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040220655 Swanson et al. Nov 2004 A1
20040225321 Krolik et al. Nov 2004 A1
20040225353 McGuckin et al. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040243221 Fawzi et al. Dec 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260390 Sarac et al. Dec 2004 A1
20050010287 Macoviak et al. Jan 2005 A1
20050021136 Xie et al. Jan 2005 A1
20050033398 Seguin Feb 2005 A1
20050033402 Cully et al. Feb 2005 A1
20050043711 Corcoran et al. Feb 2005 A1
20050043757 Arad et al. Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050049696 Siess et al. Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050060016 Wu et al. Mar 2005 A1
20050060029 Le et al. Mar 2005 A1
20050065594 DiMatteo et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050075712 Biancucci et al. Apr 2005 A1
20050075717 Nguyen et al. Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075724 Svanidze et al. Apr 2005 A1
20050075730 Myers et al. Apr 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050085841 Eversull et al. Apr 2005 A1
20050085842 Eversull et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050085890 Rasmussen et al. Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050090890 Wu et al. Apr 2005 A1
20050096692 Linder et al. May 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050100580 Osborne et al. May 2005 A1
20050107822 WasDyke May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050131438 Cohn Jun 2005 A1
20050137683 Hezi-Yamit et al. Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137693 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050138689 Aukerman Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050149159 Andreas et al. Jul 2005 A1
20050165352 Henry et al. Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050165479 Drews et al. Jul 2005 A1
20050182486 Gabbay Aug 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050203818 Rotman et al. Sep 2005 A9
20050209580 Freyman Sep 2005 A1
20050228472 Case et al. Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240262 White Oct 2005 A1
20050251250 Verhoeven et al. Nov 2005 A1
20050251251 Cribier Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267560 Bates Dec 2005 A1
20050283231 Haug et al. Dec 2005 A1
20050283962 Boudjemline Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060015168 Gunderson Jan 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060155312 Levine et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060173524 Salahieh et al. Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060287668 Fawzi et al. Dec 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20070010876 Salahieh et al. Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070055340 Pryor Mar 2007 A1
20070061008 Salahieh et al. Mar 2007 A1
20070112355 Salahieh et al. May 2007 A1
20070118214 Salahieh et al. May 2007 A1
20070162107 Haug et al. Jul 2007 A1
20070173918 Dreher et al. Jul 2007 A1
20070203503 Salahieh et al. Aug 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070288089 Gurskis et al. Dec 2007 A1
20080009940 Cribier Jan 2008 A1
20080033541 Gelbart et al. Feb 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080125859 Salahieh et al. May 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080234814 Salahieh et al. Sep 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080269878 Iobbi Oct 2008 A1
20080288054 Pulnev et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090030512 Thielen et al. Jan 2009 A1
20090054969 Salahieh et al. Feb 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090093877 Keidar et al. Apr 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090216312 Straubinger et al. Aug 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090264759 Byrd Oct 2009 A1
20090264997 Salahieh et al. Oct 2009 A1
20090299462 Fawzi et al. Dec 2009 A1
20100036479 Hill et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100082089 Quadri et al. Apr 2010 A1
20100094399 Dorn et al. Apr 2010 A1
20100121434 Paul et al. May 2010 A1
20100161045 Righini Jun 2010 A1
20100185275 Richter et al. Jul 2010 A1
20100191320 Straubinger et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100219092 Salahieh et al. Sep 2010 A1
20100249908 Chau et al. Sep 2010 A1
20100280495 Paul et al. Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110257735 Salahieh et al. Oct 2011 A1
20110264196 Savage et al. Oct 2011 A1
20110276129 Salahieh et al. Nov 2011 A1
20110288634 Tuval et al. Nov 2011 A1
20110295363 Girard et al. Dec 2011 A1
20120016469 Salahieh et al. Jan 2012 A1
20120016471 Salahieh et al. Jan 2012 A1
20120022642 Haug et al. Jan 2012 A1
20120029627 Salahieh et al. Feb 2012 A1
20120041549 Salahieh et al. Feb 2012 A1
20120041550 Salahieh et al. Feb 2012 A1
20120046740 Paul et al. Feb 2012 A1
20120053683 Salahieh et al. Mar 2012 A1
20120089224 Haug et al. Apr 2012 A1
20120132547 Salahieh et al. May 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120197379 Laske et al. Aug 2012 A1
20120303113 Benichou et al. Nov 2012 A1
20120303116 Gorman et al. Nov 2012 A1
20120330409 Haug et al. Dec 2012 A1
20130013057 Salahieh et al. Jan 2013 A1
20130018457 Gregg et al. Jan 2013 A1
20130030520 Lee et al. Jan 2013 A1
20130079867 Hoffman et al. Mar 2013 A1
20130079869 Straubinger et al. Mar 2013 A1
20130096664 Goetz et al. Apr 2013 A1
20130123796 Sutton et al. May 2013 A1
20130138207 Quadri et al. May 2013 A1
20130158655 Sutton et al. Jun 2013 A1
20130158656 Sutton et al. Jun 2013 A1
20130184813 Quadri et al. Jul 2013 A1
20130190865 Anderson Jul 2013 A1
20130304199 Sutton et al. Nov 2013 A1
20140018911 Zhou et al. Jan 2014 A1
20140094904 Salahieh et al. Apr 2014 A1
20140114405 Paul et al. Apr 2014 A1
20140114406 Salahieh et al. Apr 2014 A1
20140121766 Salahieh et al. May 2014 A1
20140135912 Salahieh et al. May 2014 A1
20140243967 Salahieh et al. Aug 2014 A1
20150012085 Salahieh et al. Jan 2015 A1
20150073540 Salahieh et al. Mar 2015 A1
20150073541 Salahieh et al. Mar 2015 A1
20150127094 Salahieh et al. May 2015 A1
20160045307 Yohanan et al. Feb 2016 A1
20160199184 Ma et al. Jul 2016 A1
20170216029 Crowley Aug 2017 A1
Foreign Referenced Citations (171)
Number Date Country
2002329324 Jul 2007 AU
1338951 Mar 2002 CN
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
0103546 May 1988 EP
0144167 Nov 1989 EP
579523 Jan 1994 EP
0409929 Apr 1997 EP
0850607 Jul 1998 EP
0597967 Dec 1999 EP
1000590 May 2000 EP
1057459 Dec 2000 EP
1057460 Dec 2000 EP
1078610 Feb 2001 EP
1088529 Apr 2001 EP
0937439 Sep 2003 EP
1340473 Sep 2003 EP
1356793 Mar 2004 EP
1042045 May 2004 EP
0819013 Jun 2004 EP
1430853 Jun 2004 EP
1435879 Jul 2004 EP
1439800 Jul 2004 EP
1469797 Oct 2004 EP
1472996 Nov 2004 EP
1229864 Apr 2005 EP
1059894 Jul 2005 EP
1551274 Jul 2005 EP
1551336 Jul 2005 EP
1562515 Aug 2005 EP
1570809 Sep 2005 EP
1576937 Sep 2005 EP
1582178 Oct 2005 EP
1582179 Oct 2005 EP
1589902 Nov 2005 EP
1600121 Nov 2005 EP
1156757 Dec 2005 EP
1616531 Jan 2006 EP
1605871 Jul 2008 EP
2749254 Jun 2015 EP
2926766 Oct 2015 EP
2788217 Jul 2000 FR
2056023 Mar 1981 GB
2398245 Aug 2004 GB
1271508 Nov 1986 SU
1371700 Feb 1988 SU
9117720 Nov 1991 WO
9217118 Oct 1992 WO
9301768 Feb 1993 WO
9315693 Aug 1993 WO
9504556 Feb 1995 WO
9529640 Nov 1995 WO
9614032 May 1996 WO
9624306 Aug 1996 WO
9640012 Dec 1996 WO
9748350 Dec 1997 WO
9829057 Jul 1998 WO
9836790 Aug 1998 WO
9850103 Nov 1998 WO
9855047 Dec 1998 WO
9857599 Dec 1998 WO
9933414 Jul 1999 WO
9940964 Aug 1999 WO
9944542 Sep 1999 WO
9947075 Sep 1999 WO
9951165 Oct 1999 WO
0009059 Feb 2000 WO
2000009059 Feb 2000 WO
0041652 Jul 2000 WO
0044308 Aug 2000 WO
0044311 Aug 2000 WO
0044313 Aug 2000 WO
0045874 Aug 2000 WO
0047139 Aug 2000 WO
0067661 Nov 2000 WO
0105331 Jan 2001 WO
0106959 Feb 2001 WO
0108596 Feb 2001 WO
0110320 Feb 2001 WO
0110343 Feb 2001 WO
0135870 May 2001 WO
0149213 Jul 2001 WO
0154625 Aug 2001 WO
0162189 Aug 2001 WO
2001054625 Aug 2001 WO
0164137 Sep 2001 WO
0176510 Oct 2001 WO
0197715 Dec 2001 WO
0236048 May 2002 WO
0241789 May 2002 WO
0243620 Jun 2002 WO
0247575 Jun 2002 WO
02056955 Jul 2002 WO
02069842 Sep 2002 WO
02100297 Dec 2002 WO
03003943 Jan 2003 WO
03003949 Jan 2003 WO
03011195 Feb 2003 WO
03015851 Feb 2003 WO
03028592 Apr 2003 WO
03030776 Apr 2003 WO
03032869 Apr 2003 WO
03037222 May 2003 WO
03037227 May 2003 WO
03047468 Jun 2003 WO
03047648 Jun 2003 WO
03088873 Oct 2003 WO
03094793 Nov 2003 WO
03094797 Nov 2003 WO
03096932 Nov 2003 WO
2004006803 Jan 2004 WO
2004006804 Jan 2004 WO
2004014256 Feb 2004 WO
2004019817 Mar 2004 WO
2004021922 Mar 2004 WO
2004023980 Mar 2004 WO
2004019811 Apr 2004 WO
2004026117 Apr 2004 WO
2004041126 May 2004 WO
2004043293 May 2004 WO
2004047681 Jun 2004 WO
2004058106 Aug 2004 WO
2004066876 Aug 2004 WO
2004082536 Sep 2004 WO
2004089250 Oct 2004 WO
2004089253 Oct 2004 WO
2004093728 Nov 2004 WO
2004105651 Dec 2004 WO
2005002466 Jan 2005 WO
2005004753 Jan 2005 WO
2005009285 Feb 2005 WO
2005011534 Feb 2005 WO
2005011535 Feb 2005 WO
2005023155 Mar 2005 WO
2005027790 Mar 2005 WO
2005046528 May 2005 WO
2005046529 May 2005 WO
2005048883 Jun 2005 WO
2005065585 Jul 2005 WO
2005084595 Sep 2005 WO
2005087140 Sep 2005 WO
2005096993 Oct 2005 WO
2006005015 Jan 2006 WO
2006009690 Jan 2006 WO
2006027499 Mar 2006 WO
2005062980 May 2006 WO
2007035471 Mar 2007 WO
2005102015 Apr 2007 WO
2006138391 Apr 2007 WO
2007044285 Apr 2007 WO
2007058847 May 2007 WO
2007092354 Aug 2007 WO
2007097983 Aug 2007 WO
2007053243 Sep 2007 WO
2007033093 Jan 2008 WO
2010042950 Apr 2010 WO
2010098857 Sep 2010 WO
2012116368 Aug 2012 WO
2012162228 Nov 2012 WO
2013009975 Jan 2013 WO
2013028387 Feb 2013 WO
2013074671 May 2013 WO
2013096545 Jun 2013 WO
2016126511 Aug 2016 WO
2016183523 Nov 2016 WO
Non-Patent Literature Citations (106)
Entry
US 8,062,356 B2, 11/2011, Salahieh et al. (withdrawn)
US 8,062,357 B2, 11/2011, Salahieh et al. (withdrawn)
US 8,075,614 B2, 12/2011, Salahieh et al. (withdrawn)
US 8,133,271 B2, 03/2012, Salahieh et al. (withdrawn)
US 8,211,170 B2, 07/2012, Paul et al. (withdrawn)
Carpentier-Edwards PERIMOUNT Bioprosthesis (2003).
International Search Report and Written Opinion dated Apr. 5, 2019 for International Application No. PCT/US2019/017015.
Knudsen et al., “Catheter-implanted prosthetic heart valves.” Int'l J. of Art. Organs, 16(5): 253-262, May 1993.
Kort et al., “Minimally Invasive Aortic Valve Replacement: Echocardiographic and Clinical Results.” Am. Heart J., 142(3): 476-481, Sep. 2001.
Lawrence et al., “Percutaneous Endovascular Graft: Experimental Evaluation,” Radiology, 163(2): 357-60 (May 1987).
Levi et al., “Future of Interventional Cardiology in Pediactrics.” Current Opinion in Cardiol., 18:79-90 (2003).
Levy, “Mycobacterium chelonei Infection of Porcine Heart Valves.” The New England Journal of Medicine, Washington DC, 297(12), Sep. 22, 1977.
Love et al., The Autogenous Tissue Heart Valve: Current Status. Journal of Cardiac Surgery, 6(4): 499-507, Mar. 1991.
Lutter et al., “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation.” J. of Thoracic and Cardio. Surg., 123(4): 768-776, Apr. 2002.
Magovern et al., “Twenty-five-Year Review of the Magovern-Cromie Sutureless Aortic Valve.” Ann. Thorac. Surg., 48: S33-4 (1989).
Maraj et al., Evaluation of Hemolysis in Patients with Prosthetic Heart Valves, Clin. Cardiol. 21, 387-392 (1998).
McKay et al., “The Mansfield Scientific Aortic Valvuloplasty Registry: Overview of Acute Hemodynamic Results and Procedural Complications.” J. Am. Coll. Cardiol. 17(2): 485-91 (Feb. 1991).
Mirich et al., “Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study.” Radiology, 170: 1033-1037 (1989).
Moazami et al., “Transluminal Aortic Valve Placement: A Feasibility Study With a Newly Designed Collapsiable Aortic Valve,” ASAIO J. vol. 42:5, pp. M383-M385 (Sep./Oct. 1996).
Moulopoulos et al., “Catheter-Mounted Aortic Valves.” Annals of Thoracic Surg., 11(5): 423-430, May 1971.
Paniagua et al., “Heart Watch.” Texas Heart Institute. Edition: 8 pages, Spring, 2004.
Paniagua et al., “Percutaneous Heart Valve in the Chronic in Vitro Testing Model.” Circulation, 106: e51-e52, Sep. 17, 2002.
Parodi et al., “Transfemoral Intraluminal Graft Implantation for Abdominal Aortic Aneurysms.” Ann. Vasc. Surg, 5 (6):491-9 (1991).
Pavcnik et al., “Percutaneous Bioprosthetic Venous Valve: A Long-term Study in Sheep.” J. of Vascular Surg., 35(3): 598-603, Mar. 2002.
Pavcnik et al., “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement.” Radiology 183:151-54 (1992).
Pavcnik, et al., “Aortic and venous valve for percutaneous insertion,” Min. Invas. Ther. & Allied Technol. 9(3/4) 287-292 (2000).
Phillips et al., “A Temporary Catheter-Tip Aortic Valve: Hemodynamic Effects on Experimental Acute Aortic Insufficiency.” Annals of Thoracic Surg., 21(2): 134-136, Feb. 1976.
Printz, et al., “Let the Blood Circulate.” Sulzer Tech. Rev. Apr. 1999.
U.S. Appl. No. 60/553,945 to White.
Raillat et al., “Treatment of Iliac Artery Stenosis with the Wallstent Endoprosthesis.” AJR 154(3):613-6 (Mar. 1990).
Remadi et al., “Preliminary results of 130 aortic valve replacements with a new mechanical bileaflet prosthesis: the Edwards MIRA valve” Interactive Cardiovasc. and Thorac. Surg. 2, 80-83 (2003).
Rosch et al., “Gianturco-Rosch Expandable Z-Stents in the Treatment of Superior Vena Cava Syndrome.” Cardiovasc. Intervent. Radiol. 15: 319-327 (1992).
Schurink et al,. “Stent Attachment Site—related Endoleakage after Stent Graft Treatment: An in vitro study of the effects of graft size, stent type, and atherosclerotic wall changes.” J. Vasc. Surg., 30(4):658-67 (Oct. 1999).
Seminars in Interventional Cardiology, ed. P.W. Surreys, vol. 5 (2000).
Sochman et al., “Percutaneous Transcatheter Aortic Disc Valve Prosthesis Implantation: A Feasibility Study.” Cardiovasc. Intervent. Radiol., 23: 384-388, Sep. 2000.
Southern Lights Biomaterials Homepage, http://www.slv.co.nz/, Jan. 7, 2011.
Stanley et al., “Evaluation of Patient Selection Guidelines for Endoluminal AAA Repair With the Zenith Stent Graft: The Australasian Experience.” J. Endovasc. Ther. 8:457-464 (2001).
Thompson et al., “Endoluminal stent grafting of the thoracic aorta: Initial experience with the Gore Excluder,” Journal of Vascular Surgery, 1163-70 (Jun. 2002).
Steinhoff et al., “Tissue Engineering of Pulmonary Heart Valves on Allogenic Acellular Matrix Conduits.” Circulation, 102 [suppl. III]: III-50-III-55 (2000).
Stuart, “In Heart Valves, A Brave, New Non-Surgical World.” Start-Up. 9-17, Feb. 2004.
Supplemental Search Report from EP Patent Office, EP Application No. 04815634.3, datedAug. 19, 2011.
Supplemental Search Report from EP Patent Office, EP Application No. 05758878.2, dated Oct. 24, 2011.
Textbook of Interventional Cardiology, 2d Ed., Chapter 75: Percutaneous Expandable Prosthetic Valves (1994).
Stassano, “Mid-term Results of the Valve on Valve Technique for Bioprosthetic failure.” European journal of Ccardiothoracic Surgery:vol. 18, 453-457, Oct. 2000.
Topol, “Percutaneous Expandable Prosthetic Valves.” Textbook of Interventional Cardiology, W.B. Saunders Company, 2: 1268-1276, 1994.
Vahanian et al., “Percutaneous Approaches to Valvular Disease.” Circulation, 109: 1572-1579, Apr. 6, 2004.
Van Herwerden et al., “Percutaneous Valve Implantation: Back to the Future?” Euro. Heart J., 23(18): 1415-1416, Sep. 2002.
VentureBeatProfiles, Claudio Argento, Jan. 7, 2010, http://venturebeatprofiles.com/person/profile/claudio-argento.
Vossoughi et al., Stent Graft Update (2000)—Kononov, Volodos, and Parodi and Palmaz Stents; Hemobahn Stent Graft.
White et al., “Endoleak as a Complication of Endoluminal Grafting of Abdominal Aortic Aneurysms: Classification, Incidence, Diagnosis, and Management.” J. Endovac. Surg., 4:152-168 (1997).
Yoshioka et al., “Self-Expanding Endovascular Graft: An Experimental Study in Dogs.” AJR 151: 673-76 (Oct. 1988).
USPTO Case IPR2017-01293, U.S. Pat. No. 8,992,608 B, Oct. 13, 2017.
Zhou et al., “Self-expandable Valved Stent of Large Size: Off-Bypass Implantation in Pulmonary Position.” Eur. J. Cardiothorac, 24: 212-216, Aug. 2003.
Gore Excluder Instructions for Use (2002).
USPTO Case Ipr 2017-0006, U.S. Pat. No. 8,992,608 B2, “Final Written Decision” dated Mar. 23, 2018.
Fluency Vascular Stent Graft Instructions for Use (2003).
Cribier et al., “Percutaneous Transluminal Valvuloplasty of Acquired Aortic Stenosis in Elderly Patients: An Alternative to Valve Replacement?” The Lancet, 63-7 (Jan. 11, 1986).
Supplemental Search Report from EP Patent Office, EP Application No. 04813777.2, dated Aug. 19, 2011.
Laborde et al., “Percutaneous Implantation of the Corevalve Aortic Valve Prosthesis for Patients Presenting High Risk for Surgical Valve Replacement.” EuroIntervention: 472-474, Feb. 2006.
“A Matter of Size.” Triennial Review of the National Nanotechnology Initiative, The National Academies Press, Washington DC, v-13, http://www.nap.edu/catalog/11752/a-matter-of-size-triennial-review-of-the-national-nanotechnology, 2006.
“Heart Valve Materials—Bovine (cow).” Equine & Porcine Pericardium, Maverick Biosciences Pty. Lt, http://maverickbio.com/biological-medical-device-materials.php?htm. 2009.
“Pericardial Heart Valves.” Edwards Lifesciences, Cardiovascular Surgery FAQ, http://www.edwards.com/products/cardiovascularsurgeryfaq.htm, Nov. 14, 2010.
Allen et al., “What are the characteristics of the ideal endovascular graft for abdominal aortic aneurysm exclusion?” J. Endovasc. Surg., 4(2):195-202 (May 1997).
Andersen et al. “Transluminal catheter implantation of a new expandable artificial cardiac valve (the stent—valve) in the aorta and the beating heart of closed chest pigs (Abstract).” Eur. Heart J., 11 (Suppl.): 224a (1990).
Andersen et al., “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J., 13:704-708, May 1992.
Atwood et al., “Insertion of Heart Valves by Catheterization.” Project Supervised by Prof. S. Muftu of Northeastern University 2001-2002: 36-40, May 30, 2002.
Atwood et al., “Insertion of Heart Valves by Catheterization.” The Capstone Design Course Report. MIME 1501-1502. Technical Design Report Northeastern University, pp. 1-93, Nov. 5, 2007.
Bailey, “Percutaneous Expandable Prosthetic Valves, Textbook of Interventional Cardiology.” vol. 2, 2d ed. Eric J. Topol, W.B. Saunders Co. (1994).
Blum et al., “Endoluminal Stent—Grafts for Intrarenal Abdominal Aortic Aneurysms.” New Engl. J. Med., 336:13-20 (1997).
Bodnar et al., “Replacement Cardiac Valves R Chapter 13: Extinct Cardiac Valve Prostheses.” Pergamon Publishing Corporation. New York, 307-322, 1991.
Bonhoeffer et al., “Percutaneous Insertion of the Pulmonary Valve.” J. Am. Coll. Cardiol., 39:1664-9 (2002).
Bonhoeffer et al., “Transcatheter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study.” Circulation, 102: 813-16 (2000).
Bonhoeffer, et al., “Percutaneous replacement of pulmonary valve in a right ventricle to pulmonary-artery prosthetic conduit with valve dysfunction.” The Lancet, vol. 356, 1403-05 (Oct. 21, 2000).
Boudjemline et al., “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study.” Med Sci. Monit., vol. 8, No. 4: BR113-116, Apr. 12, 2002.
Boudjemline et al., “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs.” Euro. Heart J., 23: 1045-1049, Jul. 2002.
Boudjemline et al., “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study.” Journal of the American College of Cardiology, vol. 43(6): 1082-1087, Mar. 17, 2004.
Boudjemline et al., “Percutaneous Valve Insertion: A New Approach?” J. of Thoracic and Cardio. Surg, 125(3): 741-743, Mar. 2003.
Boudjemline et al., “Steps Toward Percutaneous Aortic Valve Replacement.” Circulation, 105: 775-778, Feb. 12, 2002.
Couper, “Surgical Aspects of Prosthetic Valve Selection,” Overview of Cardiac Surgery for the Cardiologist, Springer-Verlag New York, Inc., 131-145 (1994).
Cribier et al., “Early Experience with Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients with Calcific Aortic Stenosis.” J. of Am. Coll. of Cardio, 43(4): 698-703, Feb. 18, 2004.
Cribier et al., “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case.” Percutaneous Valve Technologies, Inc., 16 pages, Apr. 16, 2002.
Cribier et al., “Percutaneous Transcatheter Implementation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description.” Circulation, 106: 3006-3008, Dec. 10, 2002.
Cribier et al., “Trans-Cathether Implantation of Balloon-Expandable Prosthetic Heart Valves: Early Results in an Animal Model.” Circulation [suppl. II] 104(17)II-552 (Oct. 23, 2001).
Cunanan et al., “Tissue Characterization and Calcification Potential of Commercial Bioprosthetic Heart Valves.” Ann. Thorac. Surg., S417-421, May 15, 2001.
Cunliffe et al., “Glutaraldehyde Inactivation of Exotic Animal Viruses in Swine Heart Tissue.” Applied and Environmental Microbiology, Greenport, New York, 37(5): 1044-1046, May 1979.
Dake et al., “Transluminal Placement of Endovascular Stent-Grafts for the Treatment of Descending Thoracic Aortic Aneurysms.” New Engl. J. of Med., 331(26):1729-34 (1994).
Dalby et al., “Non-Surgical Aortic Valve Replacement” Br. J. Cardiol., 10:450-2 (2003).
Dhasmana, et al., “Factors Associated With Periprosthetic Leakage Following Primary Mitral Valve Replacement: With Special Consideration of Suture Technique.” Annals of Thorac. Surg. 35(2), 170-8 (Feb. 1983).
Diethrich, AAA Stent Grafts: Current Developments, J. Invasive Cardiol. 13(5) (2001).
Dolmatch et al., Stent Grafts: Current Clinical Practice (2000)—EVT Endograft and Talent Endoprosthesis.
Dotter, “Transluminally-Placed Coilspring Endarterial Tube Grafts,” Investigative Radiology, pp. 329-332 (1969).
Emery et al., “Replacement of the Aortic Valve in Patients Under 50 Years of Age: Long-Term Follow-Up of the St. Jude Medical Prosthesis.” Ann. Thorac. Surg., 75:1815-9 (2003).
Ep Search Report for Ep Application No. 06824992.9, mailed Aug. 10, 2011.
Examiner's First Report on AU Patent Application No. 2011202667, dated May 17, 2012.
Ferrari et al., “Percutaneous Transvascular Aortic Valve Replacement with Self-Expanding Stent-Valve Device.” Poster from the presentation given at SMIT 2000, 12th International Conference. Sep. 5, 2000.
Greenberg, “Abdominal Aortic Endografting: Fixation and Sealing.” J. Am. Coll. Surg. 194:1:S79-S87 (2002).
Grossi, “Impact of Minimally Invasive Valvular Heart Surgery: A Case-Control Study.” Ann. Thorac. Surg., 71:807-10 (2001).
Helmus, “Mechanical and Bioprosthetic Heart Valves in Biomaterials for Artificial Organs.” Woodhead Publishing Limited: 114-162, 2011.
Hijazi, “Transcatheter Valve Replacement: A New Era of Percutaneous Cardiac Intervention Begins.” J. of Am. College of Cardio., 43(6): 1088-1089, Mar. 17, 2004.
Hourihan et al., “Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks.” JACC, Boston, Massachusetts, 20(6): 1371-1377, Nov. 15, 1992.
Huber et al., “Do Valved Stents Compromise Coronary Flow?” European Journal of Cardio-thoracic Surgery, vol. 25: 754-759, Jan. 23, 2004.
Ing, “Stents: What's Available to the Pediatric Interventional Cardiologist?” Catheterization and Cardiovascular Interventions 57:274-386 (2002).
Ionescu, et al., “Prevalence and Clinical Significance of Incidental Paraprosthetic Valvar Regurgitation: A prospective study using transesophageal echocardiography.” Heart, 89:1316-21 (2003).
Kaiser, et al., “Surgery for Left Ventricle Outflow Obstruction: Aortic Valve Replacement and Myomectomy,” Overview of Cardiac Surgery for the Cardiologist. Springer-Verlag New York, Inc., 40-45 (1994).
Kato et al., “Traumatic Thoracic Aortic Aneurysm: Treatment with Endovascular Stent-Grafts.” Radiol., 205: 657-662 (1997).
Khonsari et al., “Cardiac Surgery: Safeguards and Pitfalls in Operative Technique.” 3d ed., 45-74 (2003).
Related Publications (1)
Number Date Country
20190240011 A1 Aug 2019 US
Provisional Applications (1)
Number Date Country
62627331 Feb 2018 US